TABLE 2.
Pharmacological effects of brexpiprazole and aripiprazole
| Drugs | ||||||||
|---|---|---|---|---|---|---|---|---|
| Items | ||||||||
| ED50 values (mg/kg, po) | Cataleptogenic liability | |||||||
| D2 antagonism/antipsychotic‐like effect | 5‐HT2A antagonism | EPS | ||||||
| APO‐induced hyperlocomotion (Rat)(a) | APO‐induced stereotyped behavior (Rat)(b) | Conditioned avoidance response (Rat)(c) | DOI‐induced head twitch (Rat) | Cataleptogenic effect (Rat)(d) | d/a ratio | d/b ratio | d/c ratio | |
| Brexpiprazole | 2.3 | 2.9 | 6.0 | 4.7 | 20 | 8.7 | 6.9 | 3.3 |
| Aripiprazole | 3.2 | 6.1 | 23 | 21 | 42 | 13.1 | 6.9 | 1.8 |
Cataleptogenic liability = (ED50 for induction of catalepsy)/(ED50 for inhibition of APO‐induced behavior) or (ED50 for inhibition of conditioned avoidance response). The data are quoted from Maeda et al. 10 , 11
Abbreviations: APO, apomorphine; DOI, (±)‐2,5‐dimethoxy‐4‐iodoamphetamine; EPS, extrapyramidal symptoms.